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This study explored the effects of long-term photobiomodulation (PBM) on the glial and neuronal or-
ganization in the striatum of aged mice. Mice aged 12 months were pretreated with PBM (670 nm) for
20 minutes per day, commencing at 5 months old and continued for 8 months. We had 2 control groups,
young at 3 months and aged at 12 months old; these mice received no treatment. Brains were aldehyde-
ﬁxed and processed for immunohistochemistry with various glial and neuronal markers. We found a
clear reduction in glial cell number, both astrocytes and microglia, in the striatum after PBM in aged
mice. By contrast, the number of 2 types of striatal interneurons (parvalbuminþ and encephalopsinþ),
together with the density of striatal dopaminergic terminals (and their midbrain cell bodies), remained
unchanged after such treatment. In summary, our results indicated that long-term PBM had beneﬁcial
effects on the aging striatum by reducing glial cell number; and furthermore, that this treatment did not
have any deleterious effects on the neurons and terminations in this nucleus.
Crown Copyright  2018 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A characteristic feature of the central nervous system in aging is
an activation of glial cells (Lynch et al., 2014; Soreq et al., 2017). For
example, many previous studies have reported amarked increase in
the number of glial cells due to aging, both astrocytes andmicroglia,
across the central nervous system (Beach et al., 1989; Unger, 1998).
For both types of glial cells, there is also an increase in their size and
immunohistochemical expression of various markers (Beach et al.,
1989; Begum et al., 2013; Conde and Streit, 2006; Cotrina and
Nedergaard, 2002; Unger, 1998).
A further feature of aging is that, in contrast to the increase
in glial cell number, there is a progressive loss of neurons. This
loss manifests after a series of intrinsic molecular changes
within the neurons leading to dysfunction and ultimately death.
Furthermore, such changes render aging neurons more suscep-
tible to insult, whether by environmental toxin or genetic
mutation, such as in Alzheimer’s or Parkinson’s disease. In fact,
aging is a major risk factor for both these neurodegenerative
disorders (Balaban et al., 2005; Kujoth et al., 2005; Linnane
et al., 1989; Salvadores et al., 2017).omy, University of Sydney,
. Tel.: þ61 29 351 2500; fax:
Mitrofanis).
evier Inc. This is an open access arThere is general agreement that a pivotal part of the intrinsic
change leading to glial and neuronal aging and death is dysfunction
of the mitochondria. Mitochondria drive neuronal function by
producing adenosine triphosphate and with aging, this ability
diminishes. This is associated with an increase in toxic reactive
oxygen species, oxidative stress, and subsequent neuronal death
(Balaban et al., 2005; Kujoth et al., 2005; Linnane et al., 1989;
Salvadores et al., 2017).
In view of these key features of aging, the development of
treatments that target a reduction of gliosis and the protection of
mitochondria in neurons have generatedmuch interest (Chaturvedi
and Beal, 2008). In this context, recent studies have shown that
relatively short-term exposure to red to infrared light
(l ¼ 600e1070 nm), or photobiomodulation (PBM), not only
reduces gliosis markedly (Begum et al., 2013; El Massri et al., b,
2016a,) but also improves mitochondrial function (Begum et al.,
2013; Eells et al., 2004; Gkotsi et al., 2014; Hamblin, 2016; Karu,
2010; Khan and Arany, 2015; Rojas and Gonzalez-Lima, 2011;
Sivapathasuntharam et al., 2017), in both aging and disease.
In this study, we explored whether long-term PBM had any
impact, beneﬁcial or deleterious, on gliosis and/or neuronal survival
in aging. We chose the caudate-putamen complex, or striatum, of
the basal ganglia for investigation mainly because of our
long-standing interest in Parkinson’s disease (El Masri et al.,
2016a,b; Shaw et al., 2010), and that it represents a central “hub”
of functional neurotransmission for many other neural centers,ticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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in the basal ganglia (Parent and Hazrati, 1995). Furthermore, except
for features of the dopaminergic system (Darbin, 2012), few studies
have explored the glial and neuronal organization of the striatum,
together with the greater basal ganglia, in aging. Indeed, no pre-
vious study has explored the effects of PBM in this key brain area in
aging. To this end, we examined several cellular structures of the
striatum, namely, the 2 types of glial cells (glial ﬁbrillary acidic
protein [GFAP]þ astrocytes and ionized calcium-binding adapter
molecule 1 [IBA1]þ microglia), 2 types of neurons (parvalbumin
[Pv]þ and encephalopsin [Eno]þ), and 1 type of termination
(tyrosine hydroxylase [TH]þ). In general, by using these striatal
structures as examples, we aimed to gain insight into the overall
age-related changes evident in the basal ganglia and the impact
after PBM.
2. Materials and methods
2.1. Subjects
Male C57BL/6 mice (n ¼ 16) were housed on a 12-hour light/
dark cycle with unlimited access to food and water. Animals were
aged at 3 (young) or at 12 (aged) months old (examining animals at
only 1 stage for young [3 months] and using 12 months as aged is
common [e.g., Vacano et al., 2018]). All experiments were approved
by the Animal Ethics Committee of the University College London
and Home Ofﬁceelicensed procedures conforming to the UK
Animal Licence Act (1986). We had 3 groups of mice; 3m (aged
3 months, n ¼ 5; young controls, with no PBM), 12m
(aged 12months, n¼ 6; old controls, with no PBM), and 12mþ PBM
(aged 12 months, n ¼ 5; PBM treated).
2.2. Photobiomodulation
Animals in the 12m þ PBM group were treated with PBM
(670 nm) for 20 minutes per day. This treatment occurred in the
morning. Treatment commenced when the animals were 5 months
old and continued for 8 months, up until the animals reached
12 months of age. Our rationale for commencing treatment at
5 months was that at this age, mice in the wild are considered “old”,
but in other respects “normal”. We hence have used fully mature
mice (5 months) and mapped progress through to an older age
(12 months), recording any changes to this progress with or
without PBM.
2.3. Immunohistochemistry and cell analysis
Mice had their brains aldehyde-ﬁxed (4% buffered para-
formaldehyde), cryoprotected, and sectioned coronally using a
freezing microtome (El Massri et al., 2016a,b; Shaw et al., 2010).
Sections of striatum were incubated in normal goat serum (KPL)
and then in either rabbit anti-GFAP (1:500, ab7260; Abcam; to label
astrocytes), rabbit anti-IBA1 (1:1000, ab178846; Abcam; to label
microglia), rabbit anti-TH (1:500, T8700; Sigma; to label dopami-
nergic terminals), rabbit anti-Eno (1:500, ab75285; Abcam; to label
striatal neurons), or mouse anti-Pv (1:3000, P3088; Sigma; to label
striatal neurons) followed by biotinylated goat anti-rabbit or anti-
mouse IgG and then streptavidin-peroxidase complex (71-00-19;
KPL). In addition, sections of the midbrain were incubated in anti-
TH to label the dopaminergic cells that project to the striatum,
and these were processed further as described previously. Finally,
all sections were reacted in a 3,30- diaminobenzidine tetrahydro-
chloride solution (D3939; Sigma) and then coverslipped. For
controls, sections were processed as described previously except
that no primary antibody was used. These control sections wereimmunonegative. For cell analysis, the number of immunoreactive
cells in the striatum (and the midbrain) was estimated using the
optical fractionator method (Stereo Investigator; MBF Science), as
described previously (El Massri et al., 2016a,b; Shaw et al., 2010).
We also measured the density of THþ terminals in the striatum.
Bright-ﬁeld images of THþ terminals were captured under standard
illumination conditions for each section. Each image was then
processed in an identical manner using ImageJ software (NIH). For
each image, color threshold was adjusted to a set level, when the
THþ terminals were distinguished from background. Themean gray
valuewas thenmeasured for each image. The resulting values in the
striatum provided a reliable and replicable measure of the density
of THþ terminals in each image (El Massri et al., 2016a). For com-
parisons in the number of cells and density of terminations be-
tween groups, a 1-way analysis of variance (ANOVA) test was
performed, in-conjunction with a Tukey multiple comparison test
was used (GraphPad Prism).
3. Results
Our results will explore the age-related changes, and the effects
of PBM, in the striatum. The changes in glia, neurons, and terminal
patterns will be considered separately.
3.1. Glia
There were marked changes evident in both types of glial cells
following long-term PBM in the striatum of aged mice. Fig. 1A
shows a graph of the estimated total number of GFAPþ astrocytes in
the striatum in the different experimental groups. There were clear
differences in cell number between the different groups (Fig. 1A;
ANOVA: F ¼ 14; p < 0.001). There was a w60% increase in the
number of GFAPþ astrocytes between the 3m and 12m groups
(Tukey-Kramer: p < 0.0001). In the 12m þ PBM group, the number
of astrocytes was much lower than the 12m group (Tukey-Kramer:
p < 0.01), being similar to the 3m group (Tukey-Kramer: p > 0.05).
In terms of morphology and overall immunoreactivity, GFAPþ cells
of the 12m group (Fig. 1C) tended to be much larger and more
strongly labeled than those of the 3m (Fig. 1B) and 12m þ PBM
(Fig. 1D) groups. They appeared “activated”. For the IBA1þ micro-
glial cells, there were differences in cell number between the
different groups also (Fig. 1E; ANOVA: F ¼ 11; p < 0.001). Although
there were no differences in the number of IBA1þ microglia be-
tween 3m and 12m groups (Tukey-Kramer: p > 0.05), there was a
w50% reduction in cells between the 12m (and 3m) and 12 þ PBM
groups (Fig. 1E; Tukey-Kramer: p < 0.01). In terms of morphology,
we found no differences evident among IBA1þ microglia of the 3m
(Fig. 1F), 12m (Fig. 1G), and 12m þ PBM (Fig. 1H) groups; we
encountered no “activated”, amoeboid-like cells, with all cells
having the classical resting-state morphology. In summary, we
found that long-term PBM had a major effect on the number of glial
cells in the striatum of older animals.
3.2. Neurons
In contrast to the ﬁndings on the glial cells, we found no major
changes after long-term PBM in the 2 distinct neuronal types we
examined, namely those that express Pv or Eno. For Pvþ cells,
previous studies have reported that these form a subgroup of the
GABAergic (g-aminobutyric acid) interneurons in the rodent stria-
tum (Kawaguchi et al., 1995). Overall, therewere clear differences in
the numbers of Pvþ cells between the experimental groups (Fig. 2A;
ANOVA: F ¼ 31; p < 0.0001), due mainly to thew50% reduction in
their number between the 3m and 12m groups (Tukey-Kramer:
p < 0.0001). There were no major differences, however, between
Fig. 1. Graphs showing the total number of GFAPþ astrocytes (A) and of IBA1þmicroglia (E) in the striatum of the different experimental groups. Error bars indicate SEM. The symbol
(^) represents signiﬁcant difference (p < 0.01) using Tukey-Kramer multiple comparison test. Photomicrographs of GFAPþ astrocytes in the 3m (B), 12m (C), and 12m þ PBM (D)
groups and of IBA1þ microglia in the 3m (F), 12m (G), and 12m þ PBM (H) groups. Schematic diagram of the mouse forebrain (B’) adapted from a mouse atlas (Paxinos and Franklin,
2001). The red arrow indicates the approximate region where the photomicrographs of the striatum (BeD and FeH) were taken from; the bold number corresponds to the plate
number in the atlas. Scale bar ¼ 100 mm. Abbreviations: GFAP, anti-glial ﬁbrillary acidic protein; IBA1, ionized calcium-binding adapter molecule 1; PBM, photobiomodulation; SEM,
standard error mean. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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of morphology and overall immunoreactivity, Pvþ cells of the 3m
(Fig. 2B), 12m (Fig. 2C), and 12m þ PBM (Fig. 2D) groups were very
similar. For the Enoþ cells, these have been localized to a group of
interneurons also, but to a distinct set, namely the cholinergic
interneurons (El Massri et al., 2017). Unlike the Pvþ cells, there were
no substantial differences in the numbers of Enoþ cells between theexperimental groups (Fig. 2E; ANOVA: F ¼ 0.3; p ¼ 0.77), in
particular between the 3m and 12m groups and between the 12m
and 12m þ PBM groups (Tukey-Kramer: p > 0.05). In terms of
morphology and patterns of immunoreactivity, there were no
major differences evident among Enoþ cells of the 3m (Fig. 2F),
12m (Fig. 2G), and 12m þ PBM (Fig. 2H) groups. In summary, for
the 2 types of striatal interneurons we examined in this study, we
Fig. 2. Graphs showing the total number of parvalbuminþ cells (A) and of encephalopsinþ cells (E) in the striatum of the different experimental groups. Error bars indicate SEM.
Photomicrographs of parvalbuminþ cells in the 3m (Fig. 1B), 12m (Fig. 1C), and 12m þ PBM (Fig. 1D) groups and of encephalopsinþ cells in the 3m (Fig. 1F), 12m (Fig. 1G), and 12m þ
PBM (Fig. 1H) groups. Schematic diagram of the mouse forebrain (B0) adapted from a mouse atlas (Paxinos and Franklin, 2001). The red arrow indicates the approximate region
where the photomicrographs of striatum (BeD and FeH) were taken from; the bold number corresponds to the plate number in the atlas. Scale bar ¼ 100 mm. Abbreviation: PBM,
photobiomodulation; SEM, standard error mean. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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animals.
3.3. Terminal patterns
As with the 2 types of striatal interneurons, we found no
substantial differences in the mean density of striatal THþ termi-
nals in the 3 experimental groups used in this study (Fig. 3A;ANOVA: F ¼ 1.1; p ¼ 0.35). In each group, namely the 3m (Fig. 3B),
12m (Fig. 3C), and 12m þ PBM (Fig. 3D), strongly labeled THþ
terminals were seen across the nucleus, with no major zones of
lighter or no labeling. We also examined the number of THþ cell
bodies in the substantia nigra pars compacta (SNc) of the
midbrain, the main sources of the THþ terminations to the stria-
tum. Again, there were no substantial differences between the
number of THþ cells in the SNc in the different experimental
Fig. 3. Graphs showing the mean density of THþ terminals in the striatum (A) and the total number of THþ cells in the SNc of the midbrain (E) of the different experimental groups.
Error bars indicate SEM. Photomicrographs of striatal THþ terminals in the 3m (Fig. 1B), 12m (Fig. 1C), and 12m þ PBM (Fig. 1D) groups and of SNc THþ cells in the 3m (Fig. 1F), 12m
(Fig. 1G), and 12m þ PBM (Fig. 1H) groups. Schematic diagrams of the mouse forebrain (B0) and midbrain (taken H0) adapted from a mouse atlas (Paxinos and Franklin, 2001). The
red arrows in each schematic indicate the approximate regions where the corresponding photomicrographs of striatum (BeD) and SNc (FeH) were taken from; the bold number on
each schematic corresponds to the plate number in the atlas. Scale bar ¼ 100 mm. Abbreviations: TH, tyrosine hydroxylase; SNc, substantia nigra pars compacta; SNr, substantia
nigra pars reticulata; PBM, photobiomodulation; SEM, standard error mean. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web
version of this article.)
N. El Massri et al. / Neurobiology of Aging 66 (2018) 131e137 135groups (Fig. 3E; ANOVA: F ¼ 0.2; p ¼ 0.83), namely 3m (Fig. 3F),
12m (Fig. 3G), and 12m þ PBM (Fig. 3H). In summary, neither
aging nor long-term PBM had any effect on the dopaminergic
system of mice, with no changes being recorded in the density of
THþ terminations in the striatum and in the number of THþ cells in
the midbrain SNc.4. Discussion
The aim of this study was to explore the effects of long-term
PBM on the glial and neuronal organizations of the striatum in
aging. In general, our results indicated that in mice aged 12months,
PBM had a greater impact on reducing glial numbers than on
N. El Massri et al. / Neurobiology of Aging 66 (2018) 131e137136increasing neuronal ones; and furthermore, that this treatment had
no deleterious effects on either type of brain cells. The latter is a key
safety issue, particularly with regard to the use of this therapy in
humans. Speciﬁcally, we found a clear reduction in the number of
glial cells, both astrocytes and microglia, in the striatum after long-
term PBM. By contrast, the number of 2 types of interneurons,
together with the density of a major terminal input to the striatum,
remained unchanged after long-term PBM. These ﬁndings will be
the focus of the Discussion below.
Our most striking ﬁnding was that long-term PBM generated a
change in the number of glial cells in aging. These changes in
number can serve as important indicators as to the overall impact of
PBM in the aging and diseased brain (e.g., Beach et al., 1989;
Fernagut et al., 2004; Mouton et al., 2002; Ramírez et al., 2001)
and have been used by many previous authors exploring different
issues and therapeutic methods in the aged and diseased neural
system (e.g., Bakalian et al., 1991; Ohm et al., 1997; Pelvig et al.,
2008; Fabricius et al., 2013; El Massri et al., b, 2016a,). For both
glial cell types, astrocytes andmicroglia, we found fewer cells in the
striatum of the 12m þ PBM than in the 12m group (Fig. 1). For the
astrocytes, their number in the 12m þ PBM group was not only
much lower than the 12m group, but it was similar to the 3m group,
indicating that PBM offset almost completely the age-related
astrogliosis in the striatum. The astrogliosis we found in the stria-
tum has also been noted in other regions of the aging brain (Beach
et al., 1989; Conde and Streit, 2006; Cotrina and Nedergaard, 2002;
Unger, 1998) and retina (Ramìrez et al., 2001). Furthermore, PBM
has been shown to reduce GFAP expression in astrocytes (and
Müller cells) in the aged retina (Begum et al., 2013). It remains to be
determined whether the reduction in the number of GFAPþ astro-
cytes we found in the striatum after PBM was due to a functional
reduction in GFAP expression within cells or to a true reduction of
the cells themselves. In line with many other studies in different
systems (e.g., Brahmachari et al., 2006), we suggest that the bulk of
the changes we found were due to a functional downregulation of
GFAP expression. Furthermore, whether this downregulation of
GFAP was in response to changes in striatal neuronal numbers or a
direct impact on the astrocytes themselves is not clear (El Massri
et al., 2016b). From our results, where we noted no PBM-induced
changes in the number of 2 neuronal types (see below), one
would assume that there was a direct impact of PBM on the
astrocytes, rather than as a secondary response to a change in
neuron number. However, a much more exhaustive investigation of
the changes in the number of many different types of striatal
neurons, well beyond the scope of this study, would establish if this
is the case. For the microglia, unlike the astrocytes, we found no
clear increase in their numbers between 3m and 12m groups,
indicating no evidence for microgliosis in our model; furthermore,
we found no activated “amoeboid-like” cells in the striatum of the
12m group. Previous studies have reported that different brain
regions and the retina all show signs of microgliosis, but at different
stages of aging. For example, the midbrain SNc develops
microgliosis in mice aged 12 months (Schumm et al., 2012),
whereas the cerebral cortex (Tremblay et al., 2012) and perhaps the
retina also (Damani et al., 2011; Ma and Wong, 2016) develop
microgliosis at a later stage, from 18e24 months. Following, it is
likely that the striatum is one of those brain regions, like the
cerebral cortex, for example, that develops microgliosis at a later
stage in aging, well after 12months of age inmice. Finally, we found
that the 12 þ PBM group, rather curiously, had many fewer
microglia cells than the 12m, as well as the 3m, group. The
signiﬁcance of this ﬁnding is not clear, but we suggest that PBM
may have had an inhibitory effect on microgliosis in the striatum,
that this treatment served as a prophylaxis to microglial
hypertrophy (Zecha et al., 2016).In contrast to the effect on glial cells in the striatum of aged
mice, our results showed that long-term PBM had no impact on the
2 types of striatal interneurons examined in this study, namely the
Pvþ and Enoþ cells. For both neuronal types, there were no differ-
ences in their number between the 12m and 12m þ PBM groups
(Fig. 2). The result was particularly relevant for the number of Pvþ
cells that, unlike the number of Enoþ cells, showed a marked
decrease from the 3m to the 12m group. This reduction was not
mitigated by PBM (Fig. 2).
The beneﬁcial outcomes of PBM are thought to involve an acti-
vation of a photoacceptor, such as cytochrome c oxidase, leading to
an increase in electron transfer in the respiratory chain within the
mitochondria and increased adenosine triphosphate production
(Begum et al., 2013; Eells et al., 2004; Gkotsi et al., 2014; Hamblin,
2016; Karu, 2010; Khan and Arany, 2015; Rojas and Gonzalez-Lima,
2011; Sivapathasuntharam et al., 2017; Weinrich et al., 2017). This,
in turns, triggers a cascade of secondary downstream signaling
pathways that collectively stimulate intrinsic neuroprotective
mechanisms (Hamblin, 2016; Khan and Arany, 2015; Rojas and
Gonzalez-Lima, 2011). With regard to our ﬁndings here, our long-
term PBM may not have been efﬁcient in activating these beneﬁ-
cial mechanisms and to prevent neuronal loss in aging, at least
among the Pvþ cells of the striatum. Perhaps a different dosage may
have been more efﬁcient; for various neurological disorders, from
Alzheimer’s to Parkinson’s disease, dosage has been reported to be
important in effectiveness of PBM as a neuroprotective agent
(Hamblin, 2016; Khan and Arany, 2015; Rojas and Gonzalez-Lima,
2011), and the same may be the case in aging.
Our analysis of the dopaminergic system, in terms of terminals
in the striatum and cell bodies in themidbrain SNc, indicated that it
remained stable in mice aged 12 months. These ﬁndings are
consistent with previous ones in animals of this age (Schumm et al.,
2012). Furthermore, our results indicated that, as with the striatal
interneurons, long-term PBM had no deleterious effects on these
key structures of the basal ganglia. After 8 months of daily expo-
sure, the density of dopaminergic terminations and the number of
their cell bodies in the 12m and 12m þ PBM groups were near
identical (Fig. 3). This result has positive implications for the safety
of long-term PBM on the dopaminergic neurons (and striatal
interneurons) and for future use in Parkinson’s disease patients
(Mitrofanis, 2017).
In conclusion, our results indicated that long-term PBM had
beneﬁcial effects on the aging brain; this treatment was effective in
reducing glial cell number and did not have any deleterious effects
on the neurons and terminations in the striatum; and that this
treatment was not toxic to these cells after such a long-term
exposure in the aged brain is a key safety issue, particularly when
considering use in humans. Future studies may explore any
functionally related changes, for example, using molecular and/or
electrophysiological methods, in the aging striatum and if there is
any impact on these changes after PBM.Disclosure statement
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